Skip to main content

Artivion, Inc. (AORT) Stock Analysis

Falling Knife setup

HoldVALUE-TRAP 2/5Moderate Confidence

Healthcare · Medical Devices

Hold if already holding. Not a fresh buy at $22.34, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Endospan; Concentration risk — Supplier: AMDS sole manufacturer.

Artivion manufactures and distributes medical devices and implantable human tissues for cardiac and vascular surgical procedures across four product families: aortic stent grafts, On-X mechanical heart valves, BioGlue surgical sealant, and preservation services. Revenue comes... Read more

$22.34+64.1% A.UpsideScore 5.6/10#12 of 40 Medical Devices
QualityF-score9 / 9FCF yield-0.63%
Stop $21.14Target $37.30(analyst − 13%)A.R:R 4.3:1
Analyst target$42.88+91.9%8 analysts
$37.30our TP
$22.34price
$42.88mean
$48

Hold if already holding. Not a fresh buy at $22.34, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Endospan; Concentration risk — Supplier: AMDS sole manufacturer. Chart setup: Death cross, below all MAs, RSI 21, MACD bearish. Mixed signals. Hold existing position. Score 5.6/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Recent Developments — Artivion, Inc.

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Earnings estimates trending UP
Strong growth profile
Risks
Concentration risk — Supplier: Endospan
Concentration risk — Supplier: AMDS sole manufacturer
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6)

Key Metrics

P/E (TTM)95.0
P/E (Fwd)29.5
Mkt Cap$1.2B
EV/EBITDA22.1
Profit Mgn2.5%
ROE3.1%
Rev Growth17.5%
Beta1.40
DividendNone
Rating analysts13

Quality Signals

Piotroski F9/9MoatNarrow

Options Flow

P/C1.00neutral
IV69%elevated

Concentration Risks(10-K Item 1A)

  • HIGHSupplierEndospan
    10-K Item 1A: 'the NEXUS family of products are solely manufactured by Endospan in Herzliya, Israel.'
  • HIGHSupplierAMDS sole manufacturer
    10-K Item 1A: 'The AMDS product is solely manufactured by a supplier in Charlotte, North Carolina'
  • HIGHProductBioGlue
    10-K Item 1A: 'BioGlue is a significant source of our revenues, and as such, any risk adversely affecting our BioGlue products or business would likely be material to our financial results.'
  • HIGHProductaortic stent grafts
    10-K Item 1A: 'Aortic stent grafts are a significant source of our revenues, and as such, any risk adversely affecting aortic stent grafts would likely be material to our financial results.'
  • HIGHProductOn-X products
    10-K Item 1A: 'On-X products are a significant source of our revenues, and as such, any risk adversely affecting our On-X products or business would likely be material to our financial results.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
2.9
Quality Rank
3.5
Growth Rank
7.8

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Ma Position
2.2
Volume
2.9
Rsi
3.0
Obv
10.0
Capitulation risk (RSI 21, below 200MA)Volume accumulation (rising OBV)Below 200-MA but MA still rising (+0.8%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 3.6<4.5A.R:R 4.3 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Aggressive
RSI
21 · Oversold
20D MA 50D MA 200D MADEATH CROSSSupport $19.16Resistance $38.23

Price Targets

$21
$37
A.Upside+67.0%
A.R:R4.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Momentum score 3.6/10 — below 4.5 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-06 (79d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is AORT stock a buy right now?

Hold if already holding. Not a fresh buy at $22.34, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Endospan; Concentration risk — Supplier: AMDS sole manufacturer. Chart setup: Death cross, below all MAs, RSI 21, MACD bearish. Mixed signals. Hold existing position. Target $37.30 (+67.0%), stop $21.14 (−5.7%), A.R:R 4.3:1. Score 5.6/10, moderate confidence.

What is the AORT stock price target?

Take-profit target: $37.30 (+64.1% upside). Target $37.30 (+67.0%), stop $21.14 (−5.7%), A.R:R 4.3:1. Stop-loss: $21.14.

What are the risks of investing in AORT?

Concentration risk — Supplier: Endospan; Concentration risk — Supplier: AMDS sole manufacturer; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6).

Is AORT overvalued or undervalued?

Artivion, Inc. trades at a P/E of 95.0 (forward 29.5). TrendMatrix value score: 5.8/10. Verdict: Hold.

What do analysts say about AORT?

13 analysts cover AORT with a consensus score of 4.3/5. Average price target: $43.

What does Artivion, Inc. do?Artivion manufactures and distributes medical devices and implantable human tissues for cardiac and vascular surgical...

Artivion manufactures and distributes medical devices and implantable human tissues for cardiac and vascular surgical procedures across four product families: aortic stent grafts, On-X mechanical heart valves, BioGlue surgical sealant, and preservation services. Revenue comes from Medical Devices and Preservation Services segments sold globally, with BioGlue, aortic stent grafts, and On-X each described as significant revenue sources.

Related stocks: GMED (Globus Medical, Inc.) · PODD (Insulet Corporation) · LIVN (LivaNova PLC) · ENOV (Enovis Corporation) · ATEC (Alphatec Holdings, Inc.)